Third, correlative studies of biomarkers driven by STAT3 activity, signaling pathway abnormalities, and/or immunotherapy (e.g., PD-1/ PD-L1 expression on the tumor or tumor-infiltrating cells) were not performed. The gene discussed is CD274; the disease is neoplasm.